Fibroblast growth factor (FGF) signaling plays critical roles in key biological 
processes ranging from embryogenesis to wound healing and has strong links to 
several hallmarks of cancer. Genetic alterations in FGF receptor (FGFR) family 
members are associated with increased tumor growth, metastasis, angiogenesis, 
and decreased survival. JNJ-42756493, erdafitinib, is an orally active small 
molecule with potent tyrosine kinase inhibitory activity against all four FGFR 
family members and selectivity versus other highly related kinases. JNJ-42756493 
shows rapid uptake into the lysosomal compartment of cells in culture, which is 
associated with prolonged inhibition of FGFR signaling, possibly due to 
sustained release of the inhibitor. In xenografts from human tumor cell lines or 
patient-derived tumor tissue with activating FGFR alterations, JNJ-42756493 
administration results in potent and dose-dependent antitumor activity 
accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in 
tumors. The results of the current study provide a strong rationale for the 
clinical investigation of JNJ-42756493 in patients with tumors harboring FGFR 
pathway alterations. Mol Cancer Ther; 16(6); 1010-20. ©2017 AACR.